Ahn So-Hyeon, Choi Nam-Kyong, Kim Ye-Jee, Seong Jong-Mi, Shin Ju-Young, Jung Sun-Young, Park Byung-Joo
Korea Institute of Drug Safety and Risk Management, Seoul, Korea.
Arch Pharm Res. 2015 Jun;38(6):1255-62. doi: 10.1007/s12272-014-0500-8. Epub 2014 Oct 22.
This study examined 1-year persistency with cholinesterase inhibitors (ChEIs) for the treatment of elderly Alzheimer's dementia (AD) patients in Korea. Korean Health Insurance Review & Assessment Service database from January 2005 to June 2006 was used. Patients aged 65 or older with AD diagnosis who were first prescribed a ChEI were included. The 1-year persistence, persistency rate, and switching patterns during the follow-up period were identified. Mean time to drug discontinuation was analyzed, and persistency rates between different patient factors were compared. The 1-year persistency rate of newly treated 6,461 AD patients was 24.0%, while 50% of study patients discontinued treatment by 91 days from initiation. Persistency rates of female patients (22.8%), patients in rural areas (12.7%), and primary care (10.2%) were relatively low (p < 0.001). Persistency rate differed between age groups (p < 0.001). Overall proportion of switching was 6.6%. The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries. Patients less likely to remain on therapy should be especially monitored to optimize treatment persistence.
本研究调查了韩国老年阿尔茨海默病(AD)患者使用胆碱酯酶抑制剂(ChEIs)治疗的1年持续率。使用了2005年1月至2006年6月的韩国健康保险审查与评估服务数据库。纳入首次开具ChEI处方的65岁及以上AD诊断患者。确定随访期间的1年持续率、持续率和换药模式。分析停药的平均时间,并比较不同患者因素之间的持续率。6461例新治疗的AD患者的1年持续率为24.0%,而50%的研究患者在开始治疗后91天内停药。女性患者(22.8%)、农村地区患者(12.7%)和初级保健患者(10.2%)的持续率相对较低(p<0.001)。不同年龄组的持续率有所不同(p<0.001)。换药的总体比例为6.6%。韩国AD患者使用ChEIs的1年持续率未达到其他国家先前研究的水平。应特别监测不太可能继续治疗的患者,以优化治疗持续性。